Eagle Pharmaceuticals (EGRX) Competitors $3.19 0.00 (0.00%) As of 08/6/2025 11:41 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. ACRS, SLS, CLLS, VYGR, DERM, CTOR, LFVN, LIMN, CTNM, and LXEOShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Aclaris Therapeutics (ACRS), SELLAS Life Sciences Group (SLS), Cellectis (CLLS), Voyager Therapeutics (VYGR), Journey Medical (DERM), Citius Oncology (CTOR), Lifevantage (LFVN), Liminatus Pharma (LIMN), Contineum Therapeutics (CTNM), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors Aclaris Therapeutics SELLAS Life Sciences Group Cellectis Voyager Therapeutics Journey Medical Citius Oncology Lifevantage Liminatus Pharma Contineum Therapeutics Lexeo Therapeutics Eagle Pharmaceuticals (NASDAQ:EGRX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Do analysts prefer EGRX or ACRS? Aclaris Therapeutics has a consensus target price of $8.71, suggesting a potential upside of 455.05%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has higher earnings and valuation, EGRX or ACRS? Eagle Pharmaceuticals has higher revenue and earnings than Aclaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.16$35.64MN/AN/AAclaris Therapeutics$18.72M9.08-$132.07M-$1.39-1.13 Which has more risk & volatility, EGRX or ACRS? Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Do institutionals & insiders have more ownership in EGRX or ACRS? 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is EGRX or ACRS more profitable? Eagle Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -732.42%. Eagle Pharmaceuticals' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A Aclaris Therapeutics -732.42%-30.73%-22.74% Does the media prefer EGRX or ACRS? In the previous week, Aclaris Therapeutics had 7 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 7 mentions for Aclaris Therapeutics and 0 mentions for Eagle Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 0.46 beat Eagle Pharmaceuticals' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Eagle Pharmaceuticals Neutral Aclaris Therapeutics Neutral SummaryAclaris Therapeutics beats Eagle Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.43M$785.27M$5.48B$9.57BDividend YieldN/A4.84%3.99%4.18%P/E RatioN/A1.2929.8725.14Price / Sales0.1625.43422.9397.17Price / Cash0.4019.5635.9458.58Price / BookN/A6.578.105.59Net Income$35.64M-$3.92M$3.26B$265.48M7 Day PerformanceN/A-2.83%0.64%1.22%1 Month Performance-1.85%-0.30%2.42%0.39%1 Year Performance-23.13%23.98%27.60%23.47% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals1.9749 of 5 stars$3.19flatN/A-24.9%$41.43M$257.55M0.00100Gap DownACRSAclaris Therapeutics2.0212 of 5 stars$1.56+2.0%$8.71+458.6%+31.9%$165.67M$18.72M-1.12100News CoverageEarnings ReportSLSSELLAS Life Sciences Group2.233 of 5 stars$1.59-4.2%$7.00+340.3%+36.8%$165.63M$1M-4.1810Upcoming EarningsCLLSCellectis2.2194 of 5 stars$3.02+2.4%$4.00+32.5%+31.0%$163.97M$49.22M-3.51290Earnings ReportGap UpVYGRVoyager Therapeutics3.9207 of 5 stars$3.21+8.4%$13.39+317.1%-54.3%$163.80M$80M-2.20100Analyst ForecastHigh Trading VolumeDERMJourney Medical1.7306 of 5 stars$7.14+2.1%$9.50+33.1%+48.4%$162.84M$56.13M-18.3190News CoverageUpcoming EarningsCTORCitius Oncology1.0606 of 5 stars$2.06flat$3.00+45.6%N/A$161.44MN/A0.00N/ALFVNLifevantage4.0702 of 5 stars$13.29+5.6%$30.50+129.5%+72.5%$158.36M$200.16M19.26260LIMNLiminatus PharmaN/A$5.09-14.2%N/AN/A$154.27MN/A0.00N/ACTNMContineum Therapeutics2.4425 of 5 stars$5.80-2.7%$22.50+287.9%-60.1%$154.19M$50M-2.9431Earnings ReportUpcoming EarningsLXEOLexeo Therapeutics2.3573 of 5 stars$4.77+3.5%$17.17+259.9%-62.0%$153.04M$650K-1.4558Upcoming Earnings Related Companies and Tools Related Companies ACRS Alternatives SLS Alternatives CLLS Alternatives VYGR Alternatives DERM Alternatives CTOR Alternatives LFVN Alternatives LIMN Alternatives CTNM Alternatives LXEO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
